Evaluation of Blood Levels of BI 1291583 After a Single Oral Dose in Adults With and Without Liver Impairment

What this Trial Is About

Researchers are evaluating how the medicine BI 1291583 is absorbed into the blood in adults aged 18 to 80 years, including those with and without liver problems. This medicine is being developed to treat bronchiectasis, a long-term lung disease. Because many people with bronchiectasis also have liver issues, the study aims to understand whether liver function affects how BI 1291583 is processed in the body. Participants receive a single oral dose of BI 1291583. They are divided into four groups based on liver function healthy individuals and those with mild, moderate, or severe liver impairment. Each participant without liver problems is matched with others in the liver impairment groups based on age, sex, smoking habits, and body weight to allow accurate comparisons. The study lasts about three months, including a three-day stay at the study site and up to nine additional visits. During these visits, doctors collect health information and regularly take blood samples to measure how much BI 1291583 is in the blood over time. Participants health is closely monitored for any side effects throughout the study.

A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems